RPLP2

Across TCGA pan-cancer cohorts, RPLP2 RNA differs between tumor and matched normal tissue in 10 of 18 cancer types tested, making tumor–normal expression one of RPLP2’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where RPLP2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RPLP2 is over-expressed in tumor, although a few such as BRCA show the opposite, repressed pattern.

KIRC, COAD, and LIHC are the cancer types where RPLP2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RPLP2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	IV	+0.950	<.001	12	view →
COAD	Female	II,III,IV	+0.957	<.001	11	view →
LIHC	Female	II,III,IV	+1.290	<.001	9	view →
KIRP	All	II,III,IV	+0.861	<.001	8	view →
BRCA	Female	II,III,IV	−0.691	<.001	6	view →
THCA	Male	All	+0.374	.006	4	view →
LUSC	Male	All	+0.265	.002	4	view →
CHOL	Male	All	+2.324	<.001	3	view →
STAD	All	II,III,IV	+0.354	.031	3	view →
ESCA	All	All	+0.697	.033	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 10 strongest of 10 lineages.

RPLP2–KIRC

Open the KIRC breakdown →